| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |